PMID- 21373785
OWN - NLM
STAT- MEDLINE
DCOM- 20121207
LR  - 20211020
IS  - 1437-160X (Electronic)
IS  - 0172-8172 (Print)
IS  - 0172-8172 (Linking)
VI  - 32
IP  - 6
DP  - 2012 Jun
TI  - Killer immunoglobulin-like receptor and human leukocyte antigen-C genotypes in 
      rheumatoid arthritis primary responders and non-responders to anti-TNF-alpha therapy.
PG  - 1647-53
LID - 10.1007/s00296-011-1838-6 [doi]
AB  - The identification of patients who will respond to anti-tumor necrosis factor 
      alpha (anti-TNF-alpha) therapy will improve the efficacy, safety, and economic impact 
      of these agents. We investigated whether killer cell immunoglobulin-like receptor 
      (KIR) genes are related to response to anti-TNF-alpha therapy in patients with 
      rheumatoid arthritis (RA). Sixty-four RA patients and 100 healthy controls were 
      genotyped for 16 KIR genes and human leukocyte antigen-C (HLA-C) group 1/2 using 
      polymerase chain reaction sequence-specific oligonucleotide probes (PCR-SSOP). 
      Each patient received anti-TNF-alpha therapy (adalimumab, etanercept, or infliximab), 
      and clinical responses were evaluated after 3 months using the disease activity 
      score in 28 joints (DAS28). We investigated the correlations between the 
      carriership of KIR genes, HLA-C group 1/2 genes, and clinical data with response 
      to therapy. Patients responding to therapy showed a significantly higher 
      frequency of KIR2DS2/KIR2DL2 (67.7% R vs. 33.3% NR; P = 0.012). A positive 
      clinical outcome was associated with an activating KIR-HLA genotype; KIR2DS2 (+) 
      HLA-C group 1/2 homozygous. Inversely, non-response was associated with the 
      relatively inhibitory KIR2DS2 (-) HLA-C group 1/2 heterozygous genotype. The KIR 
      and HLA-C genotype of an RA patient may provide predictive information for 
      response to anti-TNF-alpha therapy.
FAU - McGeough, Cathy M
AU  - McGeough CM
AD  - Biomedical Sciences Research Institute, University of Ulster at Coleraine, 
      Cromore Road, Northern Ireland, UK. cathymcgeough@hotmail.co.uk
FAU - Berrar, Daniel
AU  - Berrar D
FAU - Wright, Gary
AU  - Wright G
FAU - Mathews, Clare
AU  - Mathews C
FAU - Gilmore, Paula
AU  - Gilmore P
FAU - Cunningham, Rodat T
AU  - Cunningham RT
FAU - Bjourson, Anthony J
AU  - Bjourson AJ
LA  - eng
PT  - Comparative Study
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
DEP - 20110304
PL  - Germany
TA  - Rheumatol Int
JT  - Rheumatology international
JID - 8206885
RN  - 0 (Antibodies, Monoclonal)
RN  - 0 (Antibodies, Monoclonal, Humanized)
RN  - 0 (Antirheumatic Agents)
RN  - 0 (HLA-C Antigens)
RN  - 0 (Immunoglobulin G)
RN  - 0 (KIR2DL2 protein, human)
RN  - 0 (KIR2DS2 protein, human)
RN  - 0 (Receptors, KIR)
RN  - 0 (Receptors, KIR2DL2)
RN  - 0 (Receptors, Tumor Necrosis Factor)
RN  - 0 (Tumor Necrosis Factor-alpha)
RN  - B72HH48FLU (Infliximab)
RN  - FYS6T7F842 (Adalimumab)
RN  - OP401G7OJC (Etanercept)
SB  - IM
MH  - Adalimumab
MH  - Adult
MH  - Aged
MH  - Antibodies, Monoclonal/therapeutic use
MH  - Antibodies, Monoclonal, Humanized/therapeutic use
MH  - Antirheumatic Agents/*therapeutic use
MH  - Arthritis, Rheumatoid/diagnosis/*drug therapy/genetics/immunology
MH  - Case-Control Studies
MH  - Chi-Square Distribution
MH  - Etanercept
MH  - Female
MH  - HLA-C Antigens/*genetics
MH  - Heterozygote
MH  - Homozygote
MH  - Humans
MH  - Immunoglobulin G/therapeutic use
MH  - Infliximab
MH  - Male
MH  - Middle Aged
MH  - Northern Ireland
MH  - Patient Selection
MH  - Pharmacogenetics
MH  - Phenotype
MH  - Polymerase Chain Reaction
MH  - Precision Medicine
MH  - Receptors, KIR/*genetics
MH  - Receptors, KIR2DL2/*genetics
MH  - Receptors, Tumor Necrosis Factor/therapeutic use
MH  - Risk Assessment
MH  - Risk Factors
MH  - Severity of Illness Index
MH  - Time Factors
MH  - Treatment Failure
MH  - Tumor Necrosis Factor-alpha/*antagonists & inhibitors/immunology
PMC - PMC3364412
EDAT- 2011/03/05 06:00
MHDA- 2012/12/12 06:00
PMCR- 2011/03/04
CRDT- 2011/03/05 06:00
PHST- 2010/07/29 00:00 [received]
PHST- 2011/02/18 00:00 [accepted]
PHST- 2011/03/05 06:00 [entrez]
PHST- 2011/03/05 06:00 [pubmed]
PHST- 2012/12/12 06:00 [medline]
PHST- 2011/03/04 00:00 [pmc-release]
AID - 1838 [pii]
AID - 10.1007/s00296-011-1838-6 [doi]
PST - ppublish
SO  - Rheumatol Int. 2012 Jun;32(6):1647-53. doi: 10.1007/s00296-011-1838-6. Epub 2011 
      Mar 4.